Trial Profile
A Real World Study Evaluating the Cardiac Effects of the Migalastat in Patients with Fabry Disease having Amenable Mutations of α-Galactosidase A
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 29 Aug 2018 Results (n=6) of first 12 months presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
- 30 Sep 2017 New trial record
- 30 Aug 2017 Initial results of follow up visit 1 (n=6) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.